Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet. 2022 Dec 22:S0140-6736(22)02597-1. doi: 10.1016/S0140-6736(22)02597-1. Online ahead of print.
Lancet. 2022.
PMID: 36566761
Free PMC article.